30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

DiscGenics IDCT Study Update -

Preclinical study results demonstrated that intradiscal injection of Discogenic Cells, the active ingredient in DiscGenics' IDCT allogeneic cell therapy, may be a viable treatment for degenerative disc disease. The cells produce an extracellular matrix that may rebuild depleting tissue within the discs. Earlier this month, DiscGenics announced that the first 30 subjects have been safely treated in its first-in-human 60-patient U.S. clinical study of IDCT. An independent data safety monitoring committee reported no safety issues, and recommended that the trial continue with no changes to the protocol. (DiscGenics, 9/24/19)